« Back
Home /
Anti-Human DR5 (Drozitumab)

Anti-Human DR5 (Drozitumab)

Item no.	LEIN-LT700-50mg
Manufacturer	Leinco Technologies
Amount	50 mg
Quantity options	100 mg 1 mg 25 mg 50 mg 5 mg
Category	Antibodies Primary Antibodies
Type	Antibody Primary
Specific against	Human (Homo sapiens)
Host	Human
Purity	≥95% monomer by analytical SEC
Citations	1. Mendelson, D. et al. (2010) Clin Cancer Res. 16(4):1256-63.
NCBI	8795
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Shipping condition	Cool pack
Available
Manufacturer - Applications	Quality Tested by Leinco FC The suggested concentration for Drozitumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Country of Origin	USA
Shipping Temperature	Next Day 2-8°C
Storage Conditions	Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Background	Drozitumab is a monoclonal antibody that specifically binds to human DR5. DR5 is expressed in a variety of solid tumors and hematologic malignancies, which are characteristically resistant to apoptosis. Drozitumab is a proapoptotic receptor agonists (PARA) that induces apoptosis in a variety of human cancer cell lines and xenograft models, both alone and in tandem with other antineoplastic agents.¹ Apoptosis of cancer cells triggered by the activation of DR5, occurs without affecting most normal cell types. Anti-Human DR5 (Drozitumab) utilizes the same variable regions from the therapeutic antibody Drozitumab making it ideal for research projects.
Pathogen Testing	To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Other Applications Reported In Literature	FA Agonist WB IP IF ELISA
PubMed	DR5
Manufacturer - Expression host	HEK-293
Manufacturer - Specificity	This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Drozitumab. Clone PRO95780 recognizes human death receptor 5 (DR5). This product is for research use only.
FC Effector Activity	Active
RRID	AB_2893977
Concentration	≥ 5.0 mg/ml
Formulation	This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Product Preparation	Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Antigen Distribution	DR5 is widely expressed in adult and fetal tissues, with notably high expression on tumor cells.
Endotoxin Level	≤ 1.0 EU/mg as determined by the LAL method
Immunogen	DR5 scFv
Regulatory Status	Research Use Only (RUO). Non-Therapeutic.
Additonal Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

LEIN-LT700-50mg-safety-datasheet.pdf